整体重组酵母抗乙型肝炎病毒的初步研究

The primary study on the anti-HBV effect of whole recombinant yeast

目的 借助酵母的免疫特性,设计一种新型抗乙型肝炎病毒(HBV)治疗性疫苗,探索一种全新的可有效活化机体抗病毒免疫应答方式。方法 以基因工程技术构建内含乙型肝炎表面抗原(HBsAg)和热休克蛋白(HSP)70(1～370)-HBsAg的重组毕赤酵母,皮下免疫BALB/C小鼠,检测小鼠对HBsAg的体液及细胞免疫反应。结果 重组酵母成功诱导了小鼠体内表面抗体的产生,显示其抗原性并未受到影响。细胞免疫检测未能获得预期的结果。结论 整体重组酵母活菌具有疫苗特性,整体重组酵母用于抗HBV治疗是一个新的思路,未能检测到细胞免疫反应可能与重组酵母的用量、注射方式等有关。

Objective Based on the immunologic character of Pichia pastoris yeast, a new therapeutic vaccine, whole recombinant yeast, was used to explore a new way to activate cell-mediated anti-viral immunity. Methods The recombinant plasmids, pPIC9K/S and PIC9K/hsp(l-370)-S, were constructed by inserting the gene encoding HBsAg, HSP70 (1-370) -HBsAg into vector pPIC9K and then the recombinants were transfected into Pichia pastoris yeast, GS115, respectively. Then that recombinant yeast immunized BALB/C mice were detected for humoral and cellular immunity to HBsAg. Results Recombinant yeast successfully activated the humoral immunity to HBsAg in mice, but failed to activate the cellular immunity. Conclusion The whole recombinant yeast can be used as vaccine, but need further study for optimal way of immunization.